Overview

Ngenla is a medicine used to treat children and adolescents who are not growing at the normal rate as a result of growth hormone deficiency (lack of natural growth hormone). It is given to patients from 3 years of age.

Ngenla contains the active substance somatrogon.

Ngenla can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of children and adolescents with growth hormone deficiency.

Ngenla is available as an injection in pre-filled pens of different strengths, to be given under the skin once a week. The recommended dose is 0.66 mg per kilogram of body weight each week, adjusted by the doctor if necessary. For patients over 45 kg who require doses higher than 30 mg the dose is given as two injections. Patients or their caregivers can inject the dose themselves after appropriate training.

For more information about using Ngenla, see the package leaflet or contact your doctor or pharmacist.

In healthy patients, growth hormone is released by the pituitary gland (a gland at the base of the brain). It is important for growth during childhood and adolescence. Growth hormone also affects how the body handles proteins, fat and carbohydrates. The active substance in Ngenla, somatrogon, is a version of natural human growth hormone which has been modified by combining it with part of another human hormone called chorionic gonadotropin in a so-called recombinant hormone. Because only a part of this other hormone is used, it does not have an effect on the body, but the combination lets somatrogon remain active in the body for a longer period of time than natural growth hormone so injections do not need to be given every day.

Ngenla once a week has been shown to be at least as effective as daily somatropin (a medicine with the same structure as natural growth hormone) in promoting growth. In a main study in 224 pre-pubertal patients with growth hormone deficiency the average rate of growth over a year was 10.1 cm in those given Ngenla and 9.8 cm in those given somatropin. Other measures of growth, such as bone maturation, were also comparable between children from both groups.

The most common side effects with Ngenla (which may affect more than 1 in 10 people) are reactions at the site of injection, headache, and fever. For the full list of side effects of Ngenla, see the package leaflet.

Ngenla must not be used if the patient has an active tumour or an acute life-threatening illness. It must also not be used for promoting growth in children with closed epiphyses (when the large bones have finished growing). For the full list of restrictions, see the package leaflet.

Ngenla injected once per week was shown to be at least as effective as somatropin given by injection once per day. The safety profile of Ngenla was also comparable with somatropin, although injection site reactions were more common in patients treated with Ngenla. Longer-term effects will continue to be monitored after marketing. The majority of patients preferred once-weekly treatment compared with daily injections.

The European Medicines Agency therefore decided that the benefits of Ngenla are greater than its risks and it can be authorised for use in the EU.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ngenla have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ngenla are continuously monitored. Side effects reported with Ngenla are carefully evaluated and any necessary action taken to protect patients.

Ngenla received a marketing authorisation valid throughout the EU on 14 February 2022.

Ngenla : EPAR - Medicine Overview

български (BG) (146.88 KB - PDF)
español (ES) (123.56 KB - PDF)
čeština (CS) (144.73 KB - PDF)
dansk (DA) (120.05 KB - PDF)
Deutsch (DE) (125.27 KB - PDF)
eesti keel (ET) (109.42 KB - PDF)
ελληνικά (EL) (152.16 KB - PDF)
français (FR) (123.69 KB - PDF)
hrvatski (HR) (145.1 KB - PDF)
italiano (IT) (120.8 KB - PDF)
latviešu valoda (LV) (149.45 KB - PDF)
lietuvių kalba (LT) (141.61 KB - PDF)
magyar (HU) (144.89 KB - PDF)
Malti (MT) (148.04 KB - PDF)
Nederlands (NL) (121.46 KB - PDF)
polski (PL) (147.26 KB - PDF)
português (PT) (124.91 KB - PDF)
română (RO) (142.71 KB - PDF)
slovenčina (SK) (145.99 KB - PDF)
slovenščina (SL) (141.84 KB - PDF)
Suomi (FI) (119.26 KB - PDF)
svenska (SV) (121.26 KB - PDF)

Ngenla : EPAR - Risk management plan summary

Product information

Ngenla : EPAR - Product Information

български (BG) (2.37 MB - PDF)
español (ES) (2.49 MB - PDF)
čeština (CS) (2.3 MB - PDF)
dansk (DA) (2.27 MB - PDF)
Deutsch (DE) (2.78 MB - PDF)
eesti keel (ET) (2.64 MB - PDF)
ελληνικά (EL) (2.31 MB - PDF)
français (FR) (2.81 MB - PDF)
hrvatski (HR) (1.96 MB - PDF)
íslenska (IS) (4.41 MB - PDF)
italiano (IT) (2.28 MB - PDF)
latviešu valoda (LV) (2.31 MB - PDF)
lietuvių kalba (LT) (2.78 MB - PDF)
magyar (HU) (2.25 MB - PDF)
Malti (MT) (2.5 MB - PDF)
Nederlands (NL) (1.87 MB - PDF)
norsk (NO) (1.88 MB - PDF)
polski (PL) (3.18 MB - PDF)
português (PT) (1.57 MB - PDF)
română (RO) (2.2 MB - PDF)
slovenčina (SK) (3.98 MB - PDF)
slovenščina (SL) (2.75 MB - PDF)
Suomi (FI) (3.05 MB - PDF)
svenska (SV) (2.68 MB - PDF)

Latest procedure affecting product information: IB/0007

05/12/2022

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Ngenla : EPAR - All authorised presentations

български (BG) (37.28 KB - PDF)
español (ES) (36.65 KB - PDF)
čeština (CS) (36.59 KB - PDF)
dansk (DA) (38.3 KB - PDF)
Deutsch (DE) (37.12 KB - PDF)
eesti keel (ET) (34.95 KB - PDF)
ελληνικά (EL) (36.01 KB - PDF)
français (FR) (31.37 KB - PDF)
hrvatski (HR) (35.76 KB - PDF)
íslenska (IS) (36.99 KB - PDF)
italiano (IT) (35.74 KB - PDF)
latviešu valoda (LV) (36.81 KB - PDF)
lietuvių kalba (LT) (31.53 KB - PDF)
magyar (HU) (35.67 KB - PDF)
Malti (MT) (38.56 KB - PDF)
Nederlands (NL) (36.05 KB - PDF)
norsk (NO) (33.03 KB - PDF)
polski (PL) (36.84 KB - PDF)
português (PT) (37.45 KB - PDF)
română (RO) (36.71 KB - PDF)
slovenčina (SK) (37.11 KB - PDF)
slovenščina (SL) (35.56 KB - PDF)
Suomi (FI) (34.87 KB - PDF)
svenska (SV) (36.78 KB - PDF)

Product details

Name of medicine
Ngenla
Active substance
somatrogon
International non-proprietary name (INN) or common name
somatrogon
Therapeutic area (MeSH)
Growth and Development
Anatomical therapeutic chemical (ATC) code
H01AC08

Pharmacotherapeutic group

PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

Therapeutic indication

Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone

Authorisation details

EMA product number
EMEA/H/C/005633

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Marketing authorisation holder
Pfizer Europe MA EEIG

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Opinion adopted
16/12/2021
Marketing authorisation issued
14/02/2022
Revision
4

Assessment history

Ngenla : EPAR - Procedural steps taken and scientific information after authorisation

Ngenla : EPAR - Public Assessment Report

Ngenla : EPAR - Orphan Medicine Assessment Report

CHMP summary of positive opinion for Ngenla

This page was last updated on

How useful do you find this page?